1
|
Perlikowska R, Silva J, Alves C, Susano P, Zakłos-Szyda M, Skibska A, Adamska-Bartłomiejczyk A, Wtorek K, do Rego JC, do Rego JL, Kluczyk A, Pedrosa R. Neuroprotective and Anti-inflammatory Effects of Rubiscolin-6 Analogs with Proline Surrogates in Position 2. Neurochem Res 2024; 49:895-918. [PMID: 38117448 PMCID: PMC10901950 DOI: 10.1007/s11064-023-04070-z] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/06/2023] [Revised: 09/27/2023] [Accepted: 11/16/2023] [Indexed: 12/21/2023]
Abstract
Naturally occurring peptides, such as rubiscolins derived from spinach leaves, have been shown to possess some interesting activities. They exerted central effects, such as antinociception, memory consolidation and anxiolytic-like activity. The fact that rubiscolins are potent even when given orally makes them very promising drug candidates. The present work tested whether rubiscolin-6 (R-6, Tyr-Pro-Leu-Asp-Leu-Phe) analogs have neuroprotective and anti-inflammatory effects. These hypotheses were tested in the 6-hydroxydopamine (6-OHDA) injury model of human neuroblastoma SH-SY5Y and lipopolysaccharide (LPS)-stimulated RAW 264.7 macrophages. The determination of reactive oxygen species (ROS), mitochondrial membrane potential (MMP), Caspase-3 activity, lipid peroxidation and nitric oxide (NO) production allowed us to determine the effects of peptides on hallmarks related to Parkinson's Disease (PD) and inflammation. Additionally, we investigated the impact of R-6 analogs on serine-threonine kinase (also known as protein kinase B, AKT) and mammalian target of rapamycin (mTOR) activation. The treatment with analogs 3 (Tyr-Inp-Leu-Asp-Leu-Phe-OH), 5 (Dmt-Inp-Leu-Asp-Leu-Phe-OH) and 7 (Tyr-Inp-Leu-Asp-Leu-Phe-NH2) most effectively prevented neuronal death via attenuation of ROS, mitochondrial dysfunction and Caspase-3 activity. Peptides 5 and 7 significantly increased the protein expression of the phosphorylated-AKT (p-AKT) and phosphorylated-mTOR (p-mTOR). Additionally, selected analogs could also ameliorate LPS-mediated inflammation in macrophages via inhibition of intracellular generation of ROS and NO production. Our findings suggest that R-6 analogs exert protective effects, possibly related to an anti-oxidation mechanism in in vitro model of PD. The data shows that the most potent peptides can inhibit 6-OHDA injury by activating the PI3-K/AKT/mTOR pathway, thus playing a neuroprotective role and may provide a rational and robust approach in the design of new therapeutics or even functional foods.
Collapse
Affiliation(s)
- Renata Perlikowska
- Department of Biomolecular Chemistry, Faculty of Medicine, Medical University, Mazowiecka 6/8, 92-215, Lodz, Poland.
| | - Joana Silva
- MARE-Marine and Environmental Sciences Centre, ARNET - Aquatic Research Network, Politécnico de Leiria, 2520-630, Peniche, Portugal
| | - Celso Alves
- MARE-Marine and Environmental Sciences Centre, ARNET - Aquatic Research Network, ESTM, Politécnico de Leiria, 2520-614, Peniche, Portugal
| | - Patricia Susano
- MARE-Marine and Environmental Sciences Centre, ARNET - Aquatic Research Network, Politécnico de Leiria, 2520-630, Peniche, Portugal
| | - Małgorzata Zakłos-Szyda
- Institute of Molecular and Industrial Biotechnology, Faculty of Biotechnology and Food Sciences, Lodz University of Technology, Stefanowskiego 2/22, 90-537, Lodz, Poland
| | - Agnieszka Skibska
- Department of Biomolecular Chemistry, Faculty of Medicine, Medical University, Mazowiecka 6/8, 92-215, Lodz, Poland
| | - Anna Adamska-Bartłomiejczyk
- Department of Biomolecular Chemistry, Faculty of Medicine, Medical University, Mazowiecka 6/8, 92-215, Lodz, Poland
| | - Karol Wtorek
- Department of Biomolecular Chemistry, Faculty of Medicine, Medical University, Mazowiecka 6/8, 92-215, Lodz, Poland
| | - Jean-Claude do Rego
- Platform of Behavioural Analysis (SCAC), Inserm US51 - CNRS UAR2026 HeRaCLes, Institute For Research and Innovation in Biomedicine (IRIB), University of Rouen Normandy, Rouen, France
| | - Jean-Luc do Rego
- Platform of Behavioural Analysis (SCAC), Inserm US51 - CNRS UAR2026 HeRaCLes, Institute For Research and Innovation in Biomedicine (IRIB), University of Rouen Normandy, Rouen, France
| | - Alicja Kluczyk
- Faculty of Chemistry, University of Wroclaw, 50-383, Wroclaw, Poland
| | - Rui Pedrosa
- MARE-Marine and Environmental Sciences Centre, ARNET - Aquatic Research Network, ESTM, Politécnico de Leiria, 2520-614, Peniche, Portugal
| |
Collapse
|
2
|
Værøy H, Lahaye E, Dubessy C, Benard M, Nicol M, Cherifi Y, Takhlidjt S, do Rego JL, do Rego JC, Chartrel N, Fetissov SO. Immunoglobulin G is a natural oxytocin carrier which modulates oxytocin receptor signaling: relevance to aggressive behavior in humans. Discov Ment Health 2023; 3:21. [PMID: 37983005 PMCID: PMC10587035 DOI: 10.1007/s44192-023-00048-z] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Subscribe] [Scholar Register] [Received: 09/05/2023] [Accepted: 10/12/2023] [Indexed: 11/21/2023]
Abstract
Oxytocin is a neuropeptide produced mainly in the hypothalamus and secreted in the CNS and blood. In the brain, it plays a major role in promoting social interactions. Here we show that in human plasma about 60% of oxytocin is naturally bound to IgG which modulates oxytocin receptor signaling. Further, we found that IgG of violent aggressive inmates were characterized by lower affinity for oxytocin, causing decreased oxytocin carrier capacity and reduced receptor activation as compared to men from the general population. Moreover, peripheral administration of oxytocin together with human oxytocin-reactive IgG to resident mice in a resident-intruder test, reduced c-fos activation in several brain regions involved in the regulation of aggressive/defensive behavior correlating with the attack number and duration. We conclude that IgG is a natural oxytocin carrier protein modulating oxytocin receptor signaling which can be relevant to the biological mechanisms of aggressive behavior.
Collapse
Affiliation(s)
- Henning Værøy
- Department of Psychiatric Research, Akershus University Hospital, 1478, Nordbyhagen, Norway.
| | - Emilie Lahaye
- INSERM 1239, Neuroendocrine, Endocrine and Germinal Differentiation and Communication Laboratory, University of Rouen Normandie, 76000, Rouen, France
| | - Christophe Dubessy
- INSERM 1239, Neuroendocrine, Endocrine and Germinal Differentiation and Communication Laboratory, University of Rouen Normandie, 76000, Rouen, France
- INSERM US51, CNRS UAR 2026, Imagine Platform PRIMACEN- HeRacLeS, Institute for Research and Innovation in Biomedicine (IRIB), University of Rouen Normandie, 76000, Rouen, France
| | - Magalie Benard
- INSERM US51, CNRS UAR 2026, Imagine Platform PRIMACEN- HeRacLeS, Institute for Research and Innovation in Biomedicine (IRIB), University of Rouen Normandie, 76000, Rouen, France
| | - Marion Nicol
- INSERM 1239, Neuroendocrine, Endocrine and Germinal Differentiation and Communication Laboratory, University of Rouen Normandie, 76000, Rouen, France
| | - Yamina Cherifi
- INSERM 1239, Neuroendocrine, Endocrine and Germinal Differentiation and Communication Laboratory, University of Rouen Normandie, 76000, Rouen, France
| | - Saloua Takhlidjt
- INSERM 1239, Neuroendocrine, Endocrine and Germinal Differentiation and Communication Laboratory, University of Rouen Normandie, 76000, Rouen, France
| | - Jean-Luc do Rego
- INSERM US51, CNRS UAR 2026, Behavioral Analysis Platform SCAC-HeRacLeS, Institute for Research and Innovation in Biomedicine (IRIB), University of Rouen Normandie, 76000, Rouen, France
| | - Jean-Claude do Rego
- INSERM US51, CNRS UAR 2026, Behavioral Analysis Platform SCAC-HeRacLeS, Institute for Research and Innovation in Biomedicine (IRIB), University of Rouen Normandie, 76000, Rouen, France
| | - Nicolas Chartrel
- INSERM 1239, Neuroendocrine, Endocrine and Germinal Differentiation and Communication Laboratory, University of Rouen Normandie, 76000, Rouen, France
| | - Sergueï O Fetissov
- INSERM 1239, Neuroendocrine, Endocrine and Germinal Differentiation and Communication Laboratory, University of Rouen Normandie, 76000, Rouen, France.
| |
Collapse
|
3
|
Nicol M, Lahaye E, El Mehdi M, do Rego JL, do Rego JC, Fetissov SO. Lactobacillus salivarius and Lactobacillus gasseri supplementation reduces stress-induced sugar craving in mice. Eur Eat Disord Rev 2023. [PMID: 37365682 DOI: 10.1002/erv.3004] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/27/2023] [Revised: 04/18/2023] [Accepted: 06/12/2023] [Indexed: 06/28/2023]
Abstract
OBJECTIVE Increased intake of sweets or sugar craving may occur in response to chronic stress representing a risk factor for development of eating disorders and obesity. However, no safe treatment of stress-induced sugar craving is available. In this study we analysed effects of two Lactobacillus strains on food and sucrose intake in mice before and during their exposure to a chronic mild stress (CMS). RESEARCH METHODS & PROCEDURES C57Bl6 mice were gavaged daily for 27 days with a mix of L. salivarius (LS) LS7892 and L. gasseri (LG) LG6410 strains or with 0.9% NaCl as a control. Following 10 days of gavage, mice were individually placed into the Modular Phenotypic cages, and after 7 days of acclimation were exposed to a CMS model for 10 days. Food, water and 2% sucrose intakes as well as meal pattern were monitored. Anxiety and depressive-like behaviour were analysed by standard tests. RESULTS Exposure of mice to CMS was accompanied by increased size of sucrose intake in the control group likely reflecting the stress-induced sugar craving. A consistent, about 20% lower total sucrose intake, was observed in the Lactobacilli-treated group during stress which was mainly due to a reduced number of intakes. Lactobacilli treatment also modified the meal pattern before and during the CMS, showing a decrease of meal number and an increase of meal size with a tendency of reduced total daily food intake. Mild anti-depressive behavioural effects of the Lactobacilli mix were also present. CONCLUSION Supplementation of mice with LS LS7892 and LG LG6410 decreases sugar consumption suggesting a potential utility of these strains against stress-induced sugar craving.
Collapse
Affiliation(s)
- Marion Nicol
- Regulatory Peptides - Energy Metabolism and Motivated Behavior Team, Neuroendocrine, Endocrine and Germinal Differentiation and Communication Laboratory, Inserm UMR 1239, University of Rouen Normandie, Rouen, France
| | - Emilie Lahaye
- Regulatory Peptides - Energy Metabolism and Motivated Behavior Team, Neuroendocrine, Endocrine and Germinal Differentiation and Communication Laboratory, Inserm UMR 1239, University of Rouen Normandie, Rouen, France
| | - Mouna El Mehdi
- Regulatory Peptides - Energy Metabolism and Motivated Behavior Team, Neuroendocrine, Endocrine and Germinal Differentiation and Communication Laboratory, Inserm UMR 1239, University of Rouen Normandie, Rouen, France
| | - Jean-Luc do Rego
- University of Rouen Normandie, Inserm US51, CNRS UAR2026, Animal Behavioral Platform SCAC-HeRacLeS, Institute for Research and Innovation in Biomedicine (IRIB), Rouen, France
| | - Jean-Claude do Rego
- University of Rouen Normandie, Inserm US51, CNRS UAR2026, Animal Behavioral Platform SCAC-HeRacLeS, Institute for Research and Innovation in Biomedicine (IRIB), Rouen, France
| | - Serguei O Fetissov
- Regulatory Peptides - Energy Metabolism and Motivated Behavior Team, Neuroendocrine, Endocrine and Germinal Differentiation and Communication Laboratory, Inserm UMR 1239, University of Rouen Normandie, Rouen, France
| |
Collapse
|
4
|
Tirelle P, Salaün C, Kauffmann A, Bôle-Feysot C, Guérin C, Huré M, Goichon A, Amamou A, Breton J, do Rego JL, Déchelotte P, Achamrah N, Coëffier M. Intestinal Epithelial Toll-like Receptor 4 Deficiency Modifies the Response to the Activity-Based Anorexia Model in a Sex-Dependent Manner: A Preliminary Study. Nutrients 2022; 14:nu14173607. [PMID: 36079861 PMCID: PMC9460860 DOI: 10.3390/nu14173607] [Citation(s) in RCA: 2] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/06/2022] [Revised: 08/24/2022] [Accepted: 08/28/2022] [Indexed: 11/21/2022] Open
Abstract
The role of microbiota in eating disorders has recently emerged. Previous data reported that lipopolysaccharides induce anorexia and a decrease of body weight through the activation of toll-like receptor 4 (TLR4). In the activity-based anorexia (ABA) mouse model, an increase of TLR4 expression in intestinal epithelial cells (IEC) has been described. We thus aimed to characterize the role of TLR4 in IEC in the ABA model in male and female mice. For this purpose, Vill-CreERT2-TLR4 LoxP, which are depleted for TLR4 in IEC in response to 4-OH tamoxifen, were submitted (ABA) or not (CT) to the ABA procedure that combined free access to a running wheel and progressive time-limited access to food. We thus compared CT and ABA TLR4IEC−/− mice to CT and ABA TLR4IEC+/+ mice. In response to the ABA model, TLR4IEC+/+ male and female mice exhibited a body weight loss associated to a decrease of lean mass. In TLR4IEC−/− male mice, body weight loss was delayed and less pronounced compared to TLR4IEC+/+ male mice. We did not observe a difference of body weight loss in female mice. The body composition remained unchanged between TLR4IEC−/− and TLR4IEC+/+ mice in both sexes. In both sexes, ABA TLR4IEC+/+ mice exhibited an increase of food-anticipatory activity, as well as an increase of immobility time during the open field test. However, female TLR4IEC−/− mice showed a decrease of the time spent at the centre and an increase of the time spent at the periphery of the open field area, whereas we did not observe differences in the male mice. In conclusion, the invalidation of TLR4 in IEC modified the response to the ABA model in a sex-dependent manner. Further studies should decipher the underlying mechanisms.
Collapse
Affiliation(s)
- Pauline Tirelle
- Université de Rouen Normandie, INSERM UMR 1073 “Nutrition, Inflammation and Microbiota–Gut–Brain Axis”, 76183 Rouen, France
- Institute for Research and Innovation in Biomedicine (IRIB), Université de Rouen Normandie, 76183 Rouen, France
| | - Colin Salaün
- Université de Rouen Normandie, INSERM UMR 1073 “Nutrition, Inflammation and Microbiota–Gut–Brain Axis”, 76183 Rouen, France
- Institute for Research and Innovation in Biomedicine (IRIB), Université de Rouen Normandie, 76183 Rouen, France
| | - Alexandre Kauffmann
- Université de Rouen Normandie, INSERM UMR 1073 “Nutrition, Inflammation and Microbiota–Gut–Brain Axis”, 76183 Rouen, France
- Institute for Research and Innovation in Biomedicine (IRIB), Université de Rouen Normandie, 76183 Rouen, France
| | - Christine Bôle-Feysot
- Université de Rouen Normandie, INSERM UMR 1073 “Nutrition, Inflammation and Microbiota–Gut–Brain Axis”, 76183 Rouen, France
- Institute for Research and Innovation in Biomedicine (IRIB), Université de Rouen Normandie, 76183 Rouen, France
| | - Charlène Guérin
- Université de Rouen Normandie, INSERM UMR 1073 “Nutrition, Inflammation and Microbiota–Gut–Brain Axis”, 76183 Rouen, France
- Institute for Research and Innovation in Biomedicine (IRIB), Université de Rouen Normandie, 76183 Rouen, France
| | - Marion Huré
- Université de Rouen Normandie, INSERM UMR 1073 “Nutrition, Inflammation and Microbiota–Gut–Brain Axis”, 76183 Rouen, France
- Institute for Research and Innovation in Biomedicine (IRIB), Université de Rouen Normandie, 76183 Rouen, France
| | - Alexis Goichon
- Université de Rouen Normandie, INSERM UMR 1073 “Nutrition, Inflammation and Microbiota–Gut–Brain Axis”, 76183 Rouen, France
- Institute for Research and Innovation in Biomedicine (IRIB), Université de Rouen Normandie, 76183 Rouen, France
| | - Asma Amamou
- Université de Rouen Normandie, INSERM UMR 1073 “Nutrition, Inflammation and Microbiota–Gut–Brain Axis”, 76183 Rouen, France
- Institute for Research and Innovation in Biomedicine (IRIB), Université de Rouen Normandie, 76183 Rouen, France
| | - Jonathan Breton
- Université de Rouen Normandie, INSERM UMR 1073 “Nutrition, Inflammation and Microbiota–Gut–Brain Axis”, 76183 Rouen, France
- Institute for Research and Innovation in Biomedicine (IRIB), Université de Rouen Normandie, 76183 Rouen, France
- Department of Nutrition, Rouen University Hospital, CHU Rouen, 76031 Rouen, France
| | - Jean-Luc do Rego
- Institute for Research and Innovation in Biomedicine (IRIB), Université de Rouen Normandie, 76183 Rouen, France
- Université de Rouen Normandie, INSERM US51-CNRS UAR2026, Animal Behavioural Platform, SCAC-HeRacLeS “High-Tech Research Infrastructures for Life”, 76183 Rouen, France
| | - Pierre Déchelotte
- Université de Rouen Normandie, INSERM UMR 1073 “Nutrition, Inflammation and Microbiota–Gut–Brain Axis”, 76183 Rouen, France
- Institute for Research and Innovation in Biomedicine (IRIB), Université de Rouen Normandie, 76183 Rouen, France
- Department of Nutrition, Rouen University Hospital, CHU Rouen, 76031 Rouen, France
| | - Najate Achamrah
- Université de Rouen Normandie, INSERM UMR 1073 “Nutrition, Inflammation and Microbiota–Gut–Brain Axis”, 76183 Rouen, France
- Institute for Research and Innovation in Biomedicine (IRIB), Université de Rouen Normandie, 76183 Rouen, France
- Department of Nutrition, Rouen University Hospital, CHU Rouen, 76031 Rouen, France
| | - Moïse Coëffier
- Université de Rouen Normandie, INSERM UMR 1073 “Nutrition, Inflammation and Microbiota–Gut–Brain Axis”, 76183 Rouen, France
- Institute for Research and Innovation in Biomedicine (IRIB), Université de Rouen Normandie, 76183 Rouen, France
- Department of Nutrition, Rouen University Hospital, CHU Rouen, 76031 Rouen, France
- Correspondence: ; Tel.: +33-23-5148240
| |
Collapse
|
5
|
Leuillier M, Duflot T, Ménoret S, Messaoudi H, Djerada Z, Groussard D, Denis RG, Chevalier L, Karoui A, Panthu B, Thiébaut PA, Schmitz-Afonso I, Nobis S, Campart C, Henry T, Sautreuil C, Luquet SH, Beseme O, Féliu C, Peyret H, Nicol L, Henry JP, Renet S, Mulder P, Wan D, Tesson L, Heslan JM, Duché A, Jacques S, Ziegler F, Brunel V, Rautureau GJ, Monteil C, do Rego JL, do Rego JC, Afonso C, Hammock B, Madec AM, Pinet F, Richard V, Anegon I, Guignabert C, Morisseau C, Bellien J. CRISPR/Cas9-mediated inactivation of the phosphatase activity of soluble epoxide hydrolase prevents obesity and cardiac ischemic injury. J Adv Res 2022; 43:163-174. [PMID: 36585106 PMCID: PMC9811321 DOI: 10.1016/j.jare.2022.03.004] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/15/2021] [Revised: 02/28/2022] [Accepted: 03/02/2022] [Indexed: 01/07/2023] Open
Abstract
INTRODUCTION Although the physiological role of the C-terminal hydrolase domain of the soluble epoxide hydrolase (sEH-H) is well investigated, the function of its N-terminal phosphatase activity (sEH-P) remains unknown. OBJECTIVES This study aimed to assess in vivo the physiological role of sEH-P. METHODS CRISPR/Cas9 was used to generate a novel knock-in (KI) rat line lacking the sEH-P activity. RESULTS The sEH-P KI rats has a decreased metabolism of lysophosphatidic acids to monoacyglycerols. KI rats grew almost normally but with less weight and fat mass gain while insulin sensitivity was increased compared to wild-type rats. This lean phenotype was more marked in males than in female KI rats and mainly due to decreased food consumption and enhanced energy expenditure. In fact, sEH-P KI rats had an increased lipolysis allowing to supply fatty acids as fuel to potentiate brown adipose thermogenesis under resting condition and upon cold exposure. The potentiation of thermogenesis was abolished when blocking PPARγ, a nuclear receptor activated by intracellular lysophosphatidic acids, but also when inhibiting simultaneously sEH-H, showing a functional interaction between the two domains. Furthermore, sEH-P KI rats fed a high-fat diet did not gain as much weight as the wild-type rats, did not have increased fat mass and did not develop insulin resistance or hepatic steatosis. In addition, sEH-P KI rats exhibited enhanced basal cardiac mitochondrial activity associated with an enhanced left ventricular contractility and were protected against cardiac ischemia-reperfusion injury. CONCLUSION Our study reveals that sEH-P is a key player in energy and fat metabolism and contributes together with sEH-H to the regulation of cardiometabolic homeostasis. The development of pharmacological inhibitors of sEH-P appears of crucial importance to evaluate the interest of this promising therapeutic strategy in the management of obesity and cardiac ischemic complications.
Collapse
Affiliation(s)
- Matthieu Leuillier
- Normandy University, UniRouen, Inserm UMR1096 EnVI, FHU REMOD-VHF, F-76000 Rouen, France
| | - Thomas Duflot
- Normandy University, UniRouen, Inserm UMR1096 EnVI, FHU REMOD-VHF, F-76000 Rouen, France,Department of Pharmacology, Rouen University Hospital, F-76000 Rouen, France,Laboratory of Pharmacokinetics, Toxicology and Pharmacogenetics, Rouen University Hospital, F-76000 Rouen, France
| | - Séverine Ménoret
- Nantes Université, CHU Nantes, Inserm, CNRS, SFR Santé, Inserm UMS 016, CNRS UMS 3556, F-44000 Nantes, France,Nantes Université, CHU Nantes, Inserm, Centre de Recherche en Transplantation et Immunologie, UMR 1064, ITUN, F-44000 Nantes, France,Transgenesis Rat ImmunoPhenomic Platform, F-44000 Nantes, France
| | - Hind Messaoudi
- Normandy University, UniRouen, Inserm UMR1096 EnVI, FHU REMOD-VHF, F-76000 Rouen, France
| | - Zoubir Djerada
- Department of Pharmacology, EA 3801, SFR CAP-santé, Reims University Hospital, F-51095 Reims Cedex, France
| | - Déborah Groussard
- Normandy University, UniRouen, Inserm UMR1096 EnVI, FHU REMOD-VHF, F-76000 Rouen, France
| | - Raphaël G.P. Denis
- Unité de Biologie Fonctionnelle et Adaptative, Centre National la Recherche scientifique, Université de Paris, BFA, UMR 8251, CNRS, F-75013 Paris, France
| | - Laurence Chevalier
- Normandie University, Unirouen, INSA Rouen, CNRS, Groupe de Physique des Matériaux-UMR6634, F-76000 Rouen, France
| | - Ahmed Karoui
- Normandie Univ, UNIROUEN, UNICAEN, ABTE, F-76000 Rouen, France
| | - Baptiste Panthu
- CarMeN Laboratory, INSERM, INRA, INSA, Université Claude Bernard Lyon 1, F-69600 Oullins, France
| | | | - Isabelle Schmitz-Afonso
- Normandie Univ, COBRA, UMR 6014 and FR 3038, Université de Rouen, INSA de Rouen, CNRS, IRCOF, F-76821, Mont-Saint-Aignan, Cedex, France
| | - Séverine Nobis
- Animal Behavioral Platform (SCAC), HeRacLeS Inserm US51-CNRS UAR2026, Institute for Research and Innovation in Biomedicine (IRIB), University of Rouen Normandy, F-76183 Rouen, France
| | - Cynthia Campart
- Animal Behavioral Platform (SCAC), HeRacLeS Inserm US51-CNRS UAR2026, Institute for Research and Innovation in Biomedicine (IRIB), University of Rouen Normandy, F-76183 Rouen, France
| | - Tiphaine Henry
- Animal Behavioral Platform (SCAC), HeRacLeS Inserm US51-CNRS UAR2026, Institute for Research and Innovation in Biomedicine (IRIB), University of Rouen Normandy, F-76183 Rouen, France
| | - Camille Sautreuil
- Normandie Univ, UNIROUEN, INSERM U1245 and Rouen University Hospital, Department of Neonatal Paediatrics and Intensive Care, F-76000, Normandy Centre for Genomic and Personalized Medicine, Rouen, France
| | - Serge H. Luquet
- Unité de Biologie Fonctionnelle et Adaptative, Centre National la Recherche scientifique, Université de Paris, BFA, UMR 8251, CNRS, F-75013 Paris, France
| | - Olivia Beseme
- Univ. Lille, CHU Lille, Inserm, Institut Pasteur de Lille, U1167 - RID-AGE - Facteurs de risque et déterminants moléculaires des maladies liées au vieillissement, F-59000 Lille, France
| | - Catherine Féliu
- Department of Pharmacology, EA 3801, SFR CAP-santé, Reims University Hospital, F-51095 Reims Cedex, France
| | - Hélène Peyret
- Department of Pharmacology, EA 3801, SFR CAP-santé, Reims University Hospital, F-51095 Reims Cedex, France
| | - Lionel Nicol
- Normandy University, UniRouen, Inserm UMR1096 EnVI, FHU REMOD-VHF, F-76000 Rouen, France
| | - Jean-Paul Henry
- Normandy University, UniRouen, Inserm UMR1096 EnVI, FHU REMOD-VHF, F-76000 Rouen, France
| | - Sylvanie Renet
- Normandy University, UniRouen, Inserm UMR1096 EnVI, FHU REMOD-VHF, F-76000 Rouen, France
| | - Paul Mulder
- Normandy University, UniRouen, Inserm UMR1096 EnVI, FHU REMOD-VHF, F-76000 Rouen, France
| | - Debin Wan
- Department of Entomology and Nematology, and UCD Comprehensive Cancer Center, University of California, Davis, CA 95616, USA
| | - Laurent Tesson
- Nantes Université, CHU Nantes, Inserm, CNRS, SFR Santé, Inserm UMS 016, CNRS UMS 3556, F-44000 Nantes, France,Nantes Université, CHU Nantes, Inserm, Centre de Recherche en Transplantation et Immunologie, UMR 1064, ITUN, F-44000 Nantes, France,Transgenesis Rat ImmunoPhenomic Platform, F-44000 Nantes, France
| | - Jean-Marie Heslan
- Nantes Université, CHU Nantes, Inserm, CNRS, SFR Santé, Inserm UMS 016, CNRS UMS 3556, F-44000 Nantes, France,Nantes Université, CHU Nantes, Inserm, Centre de Recherche en Transplantation et Immunologie, UMR 1064, ITUN, F-44000 Nantes, France,GenoCellEdit Platform, F-44000 Nantes, France
| | - Angéline Duché
- Institut Cochin, U1016 INSERM - UMR8104, CNRS - Université Paris Descartes, Genom'IC Platform, Bâtiment Gustave Roussy, F-75014 Paris, France
| | - Sébastien Jacques
- Institut Cochin, U1016 INSERM - UMR8104, CNRS - Université Paris Descartes, Genom'IC Platform, Bâtiment Gustave Roussy, F-75014 Paris, France
| | - Frédéric Ziegler
- Department of General Biochemistry, Rouen University Hospital, 76000 Rouen, France
| | - Valéry Brunel
- Department of General Biochemistry, Rouen University Hospital, 76000 Rouen, France
| | - Gilles J.P. Rautureau
- Centre de Résonance Magnétique Nucléaire à Très hauts Champs (FRE 2034, CNRS, Ecole Normale Supérieure de Lyon, Université Claude Bernard Lyon 1), Université de Lyon, F-69100 Villeurbanne, France
| | | | - Jean-Luc do Rego
- Animal Behavioral Platform (SCAC), HeRacLeS Inserm US51-CNRS UAR2026, Institute for Research and Innovation in Biomedicine (IRIB), University of Rouen Normandy, F-76183 Rouen, France
| | - Jean-Claude do Rego
- Animal Behavioral Platform (SCAC), HeRacLeS Inserm US51-CNRS UAR2026, Institute for Research and Innovation in Biomedicine (IRIB), University of Rouen Normandy, F-76183 Rouen, France
| | - Carlos Afonso
- Normandie Univ, COBRA, UMR 6014 and FR 3038, Université de Rouen, INSA de Rouen, CNRS, IRCOF, F-76821, Mont-Saint-Aignan, Cedex, France
| | - Bruce Hammock
- Department of Entomology and Nematology, and UCD Comprehensive Cancer Center, University of California, Davis, CA 95616, USA
| | - Anne-Marie Madec
- CarMeN Laboratory, INSERM, INRA, INSA, Université Claude Bernard Lyon 1, F-69600 Oullins, France
| | - Florence Pinet
- Institut Cochin, U1016 INSERM - UMR8104, CNRS - Université Paris Descartes, Genom'IC Platform, Bâtiment Gustave Roussy, F-75014 Paris, France
| | - Vincent Richard
- Normandy University, UniRouen, Inserm UMR1096 EnVI, FHU REMOD-VHF, F-76000 Rouen, France,Department of Pharmacology, Rouen University Hospital, F-76000 Rouen, France
| | - Ignacio Anegon
- Nantes Université, CHU Nantes, Inserm, CNRS, SFR Santé, Inserm UMS 016, CNRS UMS 3556, F-44000 Nantes, France,Nantes Université, CHU Nantes, Inserm, Centre de Recherche en Transplantation et Immunologie, UMR 1064, ITUN, F-44000 Nantes, France,Transgenesis Rat ImmunoPhenomic Platform, F-44000 Nantes, France
| | - Christophe Guignabert
- INSERM UMR_S 999, Hôpital Marie Lannelongue, F-92350 Le Plessis-Robinson, France,Faculté de Médecine, Université Paris-Sud, Université Paris-Saclay, F-94270 Le Kremlin-Bicêtre, France
| | - Christophe Morisseau
- Department of Entomology and Nematology, and UCD Comprehensive Cancer Center, University of California, Davis, CA 95616, USA
| | - Jérémy Bellien
- Normandy University, UniRouen, Inserm UMR1096 EnVI, FHU REMOD-VHF, F-76000 Rouen, France; Department of Pharmacology, Rouen University Hospital, F-76000 Rouen, France.
| |
Collapse
|
6
|
Le Solliec MA, Arabo A, Takhlidjt S, Maucotel J, Devère M, Riancho J, Berrahmoune H, do Rego JL, do Rego JC, Bénani A, Nedelec E, Lefranc B, Leprince J, Anouar Y, Picot M, Chartrel N, Prévost G. Acute but Not Chronic Central Administration of the Neuropeptide 26RFa (QRFP) Improves Glucose Homeostasis in Obese/Diabetic Mice. Neuroendocrinology 2022; 112:1104-1115. [PMID: 35093951 DOI: 10.1159/000522287] [Citation(s) in RCA: 2] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 09/30/2021] [Accepted: 01/23/2022] [Indexed: 11/19/2022]
Abstract
INTRODUCTION The aim of the study is to investigate whether acute or chronic central administration of the hypothalamic neuropeptide 26RFa may ameliorate the glycemic control of obese/diabetic mice. METHODS Mice were treated for 4 months with a high-fat (HF) diet and received a single i.c.v. injection of 26RFa (3 µg) or a chronic i.c.v. administration of the peptide during 28 days via osmotic minipumps (25 µg/day). i.p. and oral glucose (GLU) tolerance tests, insulin (INS) tolerance test, glucose-stimulated insulin secretion (GSIS), food/water intake, horizontal/vertical activity, energy expenditure, meal pattern, and whole-body composition were monitored. In addition, 26RFa and GPR103 mRNA expressions as well as plasma 26RFa levels were evaluated by RT-QPCR and radioimmunoassay. RESULTS Acute administration of 26RFa in HF mice induced a robust antihyperglycemic effect by enhancing INS secretion, whereas chronic administration of the neuropeptide is unable to improve glucose homeostasis in these obese/diabetogenic conditions. By contrast, chronic 26RFa treatment induced an increase of the body weight accompanied with an enhanced food intake and a decreased energy expenditure. Finally, we show that the HF diet does not alter the hypothalamic expression of the 26RFa/GPR103 neuropeptidergic system nor the levels of circulating 26RFa. CONCLUSION Our data indicate that the central beneficial effect of 26RFa on glucose homeostasis, by potentiating GSIS, is preserved in HF mice. However, chronic administration of the neuropeptide is unable to balance glycemia in these pathophysiological conditions, suggesting that the hypothalamic 26RFa/GPR103 neuropeptidergic system mainly affects short-term regulation of glucose metabolism.
Collapse
Affiliation(s)
- Marie-Anne Le Solliec
- Institute for Research and Innovation in Biomedicine (IRIB), UNIROUEN, INSERM U1239, Laboratory of Neuronal and Neuroendocrine Differentiation and Communication (DC2N), Normandie University, Rouen, France
| | - Arnaud Arabo
- Institute for Research and Innovation in Biomedicine (IRIB), Department of Biological Resources (SRB), UNIROUEN, Normandie University, Rouen, France
| | - Saloua Takhlidjt
- Institute for Research and Innovation in Biomedicine (IRIB), UNIROUEN, INSERM U1239, Laboratory of Neuronal and Neuroendocrine Differentiation and Communication (DC2N), Normandie University, Rouen, France
| | - Julie Maucotel
- Institute for Research and Innovation in Biomedicine (IRIB), Department of Biological Resources (SRB), UNIROUEN, Normandie University, Rouen, France
| | - Mélodie Devère
- Institute for Research and Innovation in Biomedicine (IRIB), UNIROUEN, INSERM U1239, Laboratory of Neuronal and Neuroendocrine Differentiation and Communication (DC2N), Normandie University, Rouen, France
| | - Julien Riancho
- Institute for Research and Innovation in Biomedicine (IRIB), UNIROUEN, INSERM U1239, Laboratory of Neuronal and Neuroendocrine Differentiation and Communication (DC2N), Normandie University, Rouen, France
| | - Hind Berrahmoune
- Institute for Research and Innovation in Biomedicine (IRIB), UNIROUEN, INSERM U1239, Laboratory of Neuronal and Neuroendocrine Differentiation and Communication (DC2N), Normandie University, Rouen, France
| | - Jean-Luc do Rego
- Institute for Research and Innovation in Biomedecine (IRIB), UNIROUEN, Animal Behaviour Platform SCAC, Normandie University, Rouen, France
| | - Jean-Claude do Rego
- Institute for Research and Innovation in Biomedecine (IRIB), UNIROUEN, Animal Behaviour Platform SCAC, Normandie University, Rouen, France
| | - Alexandre Bénani
- Center for Taste and Feeding Behaviour, CNRS (UMR6265), INRA (UMR1324), AgroSup Dijon, Université de Bourgogne-Franche Comté, Dijon, France
| | - Emmanuelle Nedelec
- Center for Taste and Feeding Behaviour, CNRS (UMR6265), INRA (UMR1324), AgroSup Dijon, Université de Bourgogne-Franche Comté, Dijon, France
| | - Benjamin Lefranc
- Institute for Research and Innovation in Biomedicine (IRIB), UNIROUEN, INSERM U1239, Laboratory of Neuronal and Neuroendocrine Differentiation and Communication (DC2N), Normandie University, Rouen, France
- Cell Imaging Platform of Normandy, Normandie University, Rouen, France
| | - Jérôme Leprince
- Institute for Research and Innovation in Biomedicine (IRIB), UNIROUEN, INSERM U1239, Laboratory of Neuronal and Neuroendocrine Differentiation and Communication (DC2N), Normandie University, Rouen, France
- Cell Imaging Platform of Normandy, Normandie University, Rouen, France
| | - Youssef Anouar
- Institute for Research and Innovation in Biomedicine (IRIB), UNIROUEN, INSERM U1239, Laboratory of Neuronal and Neuroendocrine Differentiation and Communication (DC2N), Normandie University, Rouen, France
| | - Marie Picot
- Institute for Research and Innovation in Biomedicine (IRIB), UNIROUEN, INSERM U1239, Laboratory of Neuronal and Neuroendocrine Differentiation and Communication (DC2N), Normandie University, Rouen, France
| | - Nicolas Chartrel
- Institute for Research and Innovation in Biomedicine (IRIB), UNIROUEN, INSERM U1239, Laboratory of Neuronal and Neuroendocrine Differentiation and Communication (DC2N), Normandie University, Rouen, France
| | - Gaëtan Prévost
- Institute for Research and Innovation in Biomedicine (IRIB), UNIROUEN, INSERM U1239, Laboratory of Neuronal and Neuroendocrine Differentiation and Communication (DC2N), Normandie University, Rouen, France
- Department of Endocrinology, UNIROUEN, Rouen University Hospital, Diabetes and Metabolic Diseases, Normandie University, Rouen, France
| |
Collapse
|
7
|
Alsharif I, Boukhzar L, Lefranc B, Godefroy D, Aury-Landas J, Rego JLD, Rego JCD, Naudet F, Arabo A, Chagraoui A, Maltête D, Benazzouz A, Baugé C, Leprince J, Elkahloun AG, Eiden LE, Anouar Y. Cell-penetrating, antioxidant SELENOT mimetic protects dopaminergic neurons and ameliorates motor dysfunction in Parkinson's disease animal models. Redox Biol 2021; 40:101839. [PMID: 33486153 PMCID: PMC7823055 DOI: 10.1016/j.redox.2020.101839] [Citation(s) in RCA: 15] [Impact Index Per Article: 5.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/22/2020] [Revised: 12/10/2020] [Accepted: 12/15/2020] [Indexed: 02/07/2023] Open
Abstract
Parkinson's disease (PD) is a neurodegenerative disorder characterized by motor dysfunction for which there is an unmet need for better treatment options. Although oxidative stress is a common feature of neurodegenerative diseases, notably PD, there is currently no efficient therapeutic strategy able to tackle this multi-target pathophysiological process. Based on our previous observations of the potent antioxidant and neuroprotective activity of SELENOT, a vital thioredoxin-like selenoprotein, we designed the small peptide PSELT from its redox active site to evaluate its antioxidant properties in vivo, and its potential polyfunctional activity in PD models. PSELT protects neurotoxin-treated dopaminergic neurons against oxidative stress and cell death, and their fibers against neurotoxic degeneration. PSELT is cell-permeable and acts in multiple subcellular compartments of dopaminergic neurons that are vulnerable to oxidative stress. In rodent models of PD, this protective activity prevented neurodegeneration, restored phosphorylated tyrosine hydroxylase levels, and led to improved motor skills. Transcriptomic analysis revealed that gene regulation by PSELT after MPP+ treatment negatively correlates with that occurring in PD, and positively correlates with that occurring after resveratrol treatment. Mechanistically, a major impact of PSELT is via nuclear stimulation of the transcription factor EZH2, leading to neuroprotection. Overall, these findings demonstrate the potential of PSELT as a therapeutic candidate for treatment of PD, targeting oxidative stress at multiple intracellular levels.
Collapse
Affiliation(s)
- Ifat Alsharif
- UNIROUEN, Inserm U1239, Neuronal and Neuroendocrine Differentiation and Communication Laboratory, Rouen Normandie University, 76821, Mont-Saint-Aignan, France; Institute for Research and Innovation in Biomedicine, 76000, Rouen, France; Biology department, Jamoum University College, Umm Alqura University, Saudi Arabia
| | - Loubna Boukhzar
- UNIROUEN, Inserm U1239, Neuronal and Neuroendocrine Differentiation and Communication Laboratory, Rouen Normandie University, 76821, Mont-Saint-Aignan, France; Institute for Research and Innovation in Biomedicine, 76000, Rouen, France
| | - Benjamin Lefranc
- UNIROUEN, Inserm U1239, Neuronal and Neuroendocrine Differentiation and Communication Laboratory, Rouen Normandie University, 76821, Mont-Saint-Aignan, France; Institute for Research and Innovation in Biomedicine, 76000, Rouen, France; PRIMACEN, Cell Imaging Platform of Normandie, UNIROUEN, 76000, Rouen, France
| | - David Godefroy
- UNIROUEN, Inserm U1239, Neuronal and Neuroendocrine Differentiation and Communication Laboratory, Rouen Normandie University, 76821, Mont-Saint-Aignan, France; Institute for Research and Innovation in Biomedicine, 76000, Rouen, France
| | | | - Jean-Luc do Rego
- Institute for Research and Innovation in Biomedicine, 76000, Rouen, France; Behavioral Analysis Platform SCAC, Rouen Medical School, Rouen Normandie University, 76183, Rouen, France
| | - Jean-Claude do Rego
- Institute for Research and Innovation in Biomedicine, 76000, Rouen, France; Behavioral Analysis Platform SCAC, Rouen Medical School, Rouen Normandie University, 76183, Rouen, France
| | - Frédéric Naudet
- Institut des Maladies Neurodégénératives, CNRS, UMR 5293, Bordeaux University, F-33000, Bordeaux, France
| | - Arnaud Arabo
- Biological Resource Service (SRB), Faculty of Sciences and Techniques, Rouen Normandie University, 76821, Mont-Saint-Aignan, France
| | - Abdeslam Chagraoui
- UNIROUEN, Inserm U1239, Neuronal and Neuroendocrine Differentiation and Communication Laboratory, Rouen Normandie University, 76821, Mont-Saint-Aignan, France; Institute for Research and Innovation in Biomedicine, 76000, Rouen, France
| | - David Maltête
- UNIROUEN, Inserm U1239, Neuronal and Neuroendocrine Differentiation and Communication Laboratory, Rouen Normandie University, 76821, Mont-Saint-Aignan, France; Institute for Research and Innovation in Biomedicine, 76000, Rouen, France
| | - Abdelhamid Benazzouz
- Institut des Maladies Neurodégénératives, CNRS, UMR 5293, Bordeaux University, F-33000, Bordeaux, France
| | | | - Jérôme Leprince
- UNIROUEN, Inserm U1239, Neuronal and Neuroendocrine Differentiation and Communication Laboratory, Rouen Normandie University, 76821, Mont-Saint-Aignan, France; Institute for Research and Innovation in Biomedicine, 76000, Rouen, France; PRIMACEN, Cell Imaging Platform of Normandie, UNIROUEN, 76000, Rouen, France
| | - Abdel G Elkahloun
- Comparative Genomics and Cancer, Genetics Branch, National Human Genome Research Institute, National Institutes of Health, Bethesda, MD, USA
| | - Lee E Eiden
- Section on Molecular Neuroscience, National Institute of Mental Health Intramural Research Program, National Institutes of Health, Bethesda, MD, USA
| | - Youssef Anouar
- UNIROUEN, Inserm U1239, Neuronal and Neuroendocrine Differentiation and Communication Laboratory, Rouen Normandie University, 76821, Mont-Saint-Aignan, France; Institute for Research and Innovation in Biomedicine, 76000, Rouen, France.
| |
Collapse
|
8
|
Pieronne-Deperrois M, Guéret A, Djerada Z, Crochemore C, Harouki N, Henry JP, Dumesnil A, Larchevêque M, do Rego JC, do Rego JL, Nicol L, Richard V, Jaisser F, Kolkhof P, Mulder P, Monteil C, Ouvrard-Pascaud A. Mineralocorticoid receptor blockade with finerenone improves heart function and exercise capacity in ovariectomized mice. ESC Heart Fail 2021; 8:1933-1943. [PMID: 33742556 PMCID: PMC8120350 DOI: 10.1002/ehf2.13219] [Citation(s) in RCA: 15] [Impact Index Per Article: 5.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/23/2020] [Revised: 11/27/2020] [Accepted: 01/06/2021] [Indexed: 12/12/2022] Open
Abstract
Aims In post‐menopausal women, incidence of heart failure with preserved ejection fraction is higher than in men. Hormonal replacement therapies did not demonstrate benefits. We tested whether the non‐steroidal mineralocorticoid receptor antagonist finerenone limits the progression of heart failure in ovariectomized (OVX) mice with metabolic disorders. Methods and results Ovariectomy was performed in 4‐month‐old mice, treated or not at 7 months old for 1 month with finerenone (Fine) 1 mg/kg/day. Left ventricular (LV) cardiac and coronary endothelial functions were assessed by echocardiography, catheterization, and myography. Blood pressure was measured by plethysmography. Insulin and glucose tolerance tests were performed. Exercise capacity and spontaneous activity were measured on treadmill and in combined indirect calorimetric cages equipped with voluntary running wheel. OVX mice presented LV diastolic dysfunction without modification of ejection fraction compared with controls (CTL), whereas finerenone improved LV filling pressure (LV end‐diastolic pressure, mmHg: CTL 3.48 ± 0.41, OVX 6.17 ± 0.30**, OVX + Fine 3.65 ± 0.55†, **P < 0.01 vs. CTL, †P < 0.05 vs. OVX) and compliance (LV end‐diastolic pressure–volume relation, mmHg/RVU: CTL 1.65 ± 0.42, OVX 4.77 ± 0.37***, OVX + Fine 2.87 ± 0.26††, ***P < 0.001 vs. CTL, ††P < 0.01 vs. OVX). Acetylcholine‐induced endothelial‐dependent relaxation of coronary arteries was impaired in ovariectomized mice and improved by finerenone (relaxation, %: CTL 86 ± 8, OVX 38 ± 3**, OVX + Fine 83 ± 7††, **P < 0.01 vs. CTL, ††P < 0.01 vs. OVX). Finerenone improved decreased ATP production by subsarcolemmal mitochondria after ovariectomy. Weight gain, increased blood pressure, and decreased insulin and glucose tolerance in OVX mice were improved by finerenone. The exercise capacity at race was diminished in untreated OVX mice only. Spontaneous activity measurements in ovariectomized mice showed decreased horizontal movements, reduced time spent in a running wheel, and reduced VO2 and VCO2, all parameters improved by finerenone. Conclusions Finerenone improved cardiovascular dysfunction and exercise capacity after ovariectomy‐induced LV diastolic dysfunction with preserved ejection fraction.
Collapse
Affiliation(s)
| | - Alexandre Guéret
- Inserm U1096 ENVI, Rouen Medical School, UNIROUEN, Normandy University, Rouen, France
| | - Zoubir Djerada
- Pharmacology Department, Reims University Hospital, Reims, France
| | - Clément Crochemore
- EA4651 Toxemac-ABTE, Rouen Medical School, UNIROUEN, Normandy University, Rouen, France
| | - Najah Harouki
- Inserm U1096 ENVI, Rouen Medical School, UNIROUEN, Normandy University, Rouen, France
| | - Jean-Paul Henry
- Inserm U1096 ENVI, Rouen Medical School, UNIROUEN, Normandy University, Rouen, France
| | - Anaïs Dumesnil
- Inserm U1096 ENVI, Rouen Medical School, UNIROUEN, Normandy University, Rouen, France
| | - Marine Larchevêque
- Inserm U1096 ENVI, Rouen Medical School, UNIROUEN, Normandy University, Rouen, France
| | - Jean-Claude do Rego
- SCAC Behavioral Analysis Platform, Rouen Medical School, UNIROUEN, Normandy University, Rouen, France
| | - Jean-Luc do Rego
- SCAC Behavioral Analysis Platform, Rouen Medical School, UNIROUEN, Normandy University, Rouen, France
| | - Lionel Nicol
- Inserm U1096 ENVI, Rouen Medical School, UNIROUEN, Normandy University, Rouen, France
| | - Vincent Richard
- Inserm U1096 ENVI, Rouen Medical School, UNIROUEN, Normandy University, Rouen, France
| | - Frédéric Jaisser
- Inserm U1138, Cordeliers Institute, Paris-VI University, Paris, France
| | | | - Paul Mulder
- Inserm U1096 ENVI, Rouen Medical School, UNIROUEN, Normandy University, Rouen, France
| | - Christelle Monteil
- EA4651 Toxemac-ABTE, Rouen Medical School, UNIROUEN, Normandy University, Rouen, France
| | | |
Collapse
|
9
|
Breton J, Giallourou N, Nobis S, Morin A, Achamrah N, Goichon A, Belmonte L, Dechelotte P, Rego JLD, Coëffier M, Swann J. Characterizing the metabolic perturbations induced by activity-based anorexia in the C57Bl/6 mouse using 1H NMR spectroscopy. Clin Nutr 2020; 39:2428-2434. [DOI: 10.1016/j.clnu.2019.10.026] [Citation(s) in RCA: 6] [Impact Index Per Article: 1.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/19/2019] [Accepted: 10/25/2019] [Indexed: 12/17/2022]
|
10
|
El-Mehdi M, Takhlidjt S, Khiar F, Prévost G, do Rego JL, do Rego JC, Benani A, Nedelec E, Godefroy D, Arabo A, Lefranc B, Leprince J, Anouar Y, Chartrel N, Picot M. Glucose homeostasis is impaired in mice deficient in the neuropeptide 26RFa (QRFP). BMJ Open Diabetes Res Care 2020; 8:8/1/e000942. [PMID: 32114486 PMCID: PMC7050347 DOI: 10.1136/bmjdrc-2019-000942] [Citation(s) in RCA: 7] [Impact Index Per Article: 1.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 10/09/2019] [Revised: 01/09/2020] [Accepted: 01/28/2020] [Indexed: 11/03/2022] Open
Abstract
INTRODUCTION 26RFa (pyroglutamyl RFamide peptide (QRFP)) is a biologically active peptide that has been found to control feeding behavior by stimulating food intake, and to regulate glucose homeostasis by acting as an incretin. The aim of the present study was thus to investigate the impact of 26RFa gene knockout on the regulation of energy and glucose metabolism. RESEARCH DESIGN AND METHODS 26RFa mutant mice were generated by homologous recombination, in which the entire coding region of prepro26RFa was replaced by the iCre sequence. Energy and glucose metabolism was evaluated through measurement of complementary parameters. Morphological and physiological alterations of the pancreatic islets were also investigated. RESULTS Our data do not reveal significant alteration of energy metabolism in the 26RFa-deficient mice except the occurrence of an increased basal metabolic rate. By contrast, 26RFa mutant mice exhibited an altered glycemic phenotype with an increased hyperglycemia after a glucose challenge associated with an impaired insulin production, and an elevated hepatic glucose production. Two-dimensional and three-dimensional immunohistochemical experiments indicate that the insulin content of pancreatic β cells is much lower in the 26RFa-/- mice as compared with the wild-type littermates. CONCLUSION Disruption of the 26RFa gene induces substantial alteration in the regulation of glucose homeostasis, with in particular a deficit in insulin production by the pancreatic islets. These findings further support the notion that 26RFa is an important regulator of glucose homeostasis.
Collapse
|
11
|
Dominique M, Legrand R, Galmiche M, Azhar S, Deroissart C, Guérin C, do Rego JL, Leon F, Nobis S, Lambert G, Lucas N, Déchelotte P. Changes in Microbiota and Bacterial Protein Caseinolytic Peptidase B During Food Restriction in Mice: Relevance for the Onset and Perpetuation of Anorexia Nervosa. Nutrients 2019; 11:E2514. [PMID: 31635300 PMCID: PMC6835841 DOI: 10.3390/nu11102514] [Citation(s) in RCA: 16] [Impact Index Per Article: 3.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/09/2019] [Revised: 10/14/2019] [Accepted: 10/15/2019] [Indexed: 02/06/2023] Open
Abstract
Microbiota contributes to the regulation of eating behavior and might be implicated in the pathophysiology of anorexia nervosa. ClpB (Caseinolytic peptidase B) protein produced mainly by the Enterobacteriaceae family has been identified as a conformational mimetic of α-MSH, which could result in similar anorexigenic effects. The aim of this study was to highlight the role of the microbiome and the ClpB protein in deregulation and self-maintenance of anorexia pathology. Male C57Bl/6 mice were undergone to the ABA (Activity-Based Anorexia) protocol: after 5 days of acclimatization, both ABA and LFA (Limited Food Access) mice had progressively limited access to food until D17. At the end of protocol, the plasma ClpB concentration and Enterobacteriaceae DNA in colonic content were measured. As expected, dietary restriction induced lost weight in LFA and ABA mice. At D10, colonic permeability and plasma concentration of the ClpB protein were significantly increased in LFA and ABA mice vs. controls. At D17, plasma concentration of ClpB was increased in LFA and ABA mice and, it was correlated with proportion of Enterobacteriaceae in the faeces. These abnormally high ClpB concentrations and all associated factors, and therefore might contribute to the initiation and/or perpetuation of anorexia nervosa by interfering with satiety signaling.
Collapse
Affiliation(s)
- Manon Dominique
- TargEDys SA, University of Rouen Normandy, 76183 Rouen, France.
- Inserm UMR1073, Nutrition, Gut and Brain Laboratory, University of Rouen Normandy, Unirouen, 76183 Rouen, France.
- Institute for Research and Innovation in Biomedicine (IRIB), University of Rouen Normandy, Unirouen, 76183 Rouen, France.
| | - Romain Legrand
- TargEDys SA, University of Rouen Normandy, 76183 Rouen, France.
| | - Marie Galmiche
- TargEDys SA, University of Rouen Normandy, 76183 Rouen, France.
- Inserm UMR1073, Nutrition, Gut and Brain Laboratory, University of Rouen Normandy, Unirouen, 76183 Rouen, France.
- Institute for Research and Innovation in Biomedicine (IRIB), University of Rouen Normandy, Unirouen, 76183 Rouen, France.
| | - Saïda Azhar
- TargEDys SA, University of Rouen Normandy, 76183 Rouen, France.
| | | | - Charlène Guérin
- Inserm UMR1073, Nutrition, Gut and Brain Laboratory, University of Rouen Normandy, Unirouen, 76183 Rouen, France.
- Institute for Research and Innovation in Biomedicine (IRIB), University of Rouen Normandy, Unirouen, 76183 Rouen, France.
| | - Jean-Luc do Rego
- Institute for Research and Innovation in Biomedicine (IRIB), University of Rouen Normandy, Unirouen, 76183 Rouen, France.
- Animal Behavior Platform, Service Commun d'Analyse Comportementale (SCAC), University of Rouen Normandy, 76183 Rouen, France.
| | - Fatima Leon
- Institute for Research and Innovation in Biomedicine (IRIB), University of Rouen Normandy, Unirouen, 76183 Rouen, France.
- Animal Behavior Platform, Service Commun d'Analyse Comportementale (SCAC), University of Rouen Normandy, 76183 Rouen, France.
| | - Séverine Nobis
- Institute for Research and Innovation in Biomedicine (IRIB), University of Rouen Normandy, Unirouen, 76183 Rouen, France.
- Animal Behavior Platform, Service Commun d'Analyse Comportementale (SCAC), University of Rouen Normandy, 76183 Rouen, France.
| | - Grégory Lambert
- TargEDys SA, University of Rouen Normandy, 76183 Rouen, France.
| | - Nicolas Lucas
- TargEDys SA, University of Rouen Normandy, 76183 Rouen, France.
| | - Pierre Déchelotte
- TargEDys SA, University of Rouen Normandy, 76183 Rouen, France.
- Inserm UMR1073, Nutrition, Gut and Brain Laboratory, University of Rouen Normandy, Unirouen, 76183 Rouen, France.
- Institute for Research and Innovation in Biomedicine (IRIB), University of Rouen Normandy, Unirouen, 76183 Rouen, France.
- Rouen University Hospital, CHU Charles Nicolle, 76183 Rouen, France.
| |
Collapse
|
12
|
L'Huillier C, Jarbeau M, Achamrah N, Belmonte L, Amamou A, Nobis S, Goichon A, Salameh E, Bahlouli W, do Rego JL, Déchelotte P, Coëffier M. Glutamine, but not Branched-Chain Amino Acids, Restores Intestinal Barrier Function during Activity-Based Anorexia. Nutrients 2019; 11:nu11061348. [PMID: 31208031 PMCID: PMC6628073 DOI: 10.3390/nu11061348] [Citation(s) in RCA: 15] [Impact Index Per Article: 3.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/16/2019] [Revised: 06/11/2019] [Accepted: 06/13/2019] [Indexed: 12/21/2022] Open
Abstract
Background: During activity-based anorexia (ABA) in mice, enhanced paracellular permeability and reduced protein synthesis have been shown in the colon while the gut–brain axis has received increasing attention in the regulation of intestinal and mood disorders that frequently occur during anorexia nervosa, a severe eating disorder for which there is no specific treatment. In the present study, we assessed the effects of oral glutamine (Gln) or branched-chain amino acids (BCAA) supplementation during ABA to target intestinal functions, body composition and feeding behavior. Methods: C57BL/6 male mice were randomized in Control (CTRL) and ABA groups. After ABA induction, mice received, or not, either 1% Gln or 2.5% BCAA (Leu, Ile, Val) for one week in drinking water. Results: Neither Gln nor BCAA supplementation affected body weight and body composition, while only Gln supplementation slightly increased food intake. ABA mice exhibited increased paracellular permeability and reduced protein synthesis in the colonic mucosa. Oral Gln restored colonic paracellular permeability and protein synthesis and increased the mucin-2 mRNA level, whereas BCAA did not affect colonic parameters. Conclusion: In conclusion, oral Gln specifically improves colonic response during ABA. These data should be further confirmed in AN patients.
Collapse
Affiliation(s)
- Clément L'Huillier
- UNIROUEN, INSERM UMR 1073 "Nutrition, Inflammation and Gut-Brain Axis", Normandie University, 76183 Rouen, France.
- Institute of Research and Innovation in Biomedicine (IRIB), UNIROUEN, Normandie University, 76183 Rouen, France.
| | - Marine Jarbeau
- UNIROUEN, INSERM UMR 1073 "Nutrition, Inflammation and Gut-Brain Axis", Normandie University, 76183 Rouen, France.
- Institute of Research and Innovation in Biomedicine (IRIB), UNIROUEN, Normandie University, 76183 Rouen, France.
| | - Najate Achamrah
- UNIROUEN, INSERM UMR 1073 "Nutrition, Inflammation and Gut-Brain Axis", Normandie University, 76183 Rouen, France.
- Institute of Research and Innovation in Biomedicine (IRIB), UNIROUEN, Normandie University, 76183 Rouen, France.
- Department of Nutrition, Rouen University Hospital, 76183 Rouen, France.
| | - Liliana Belmonte
- UNIROUEN, INSERM UMR 1073 "Nutrition, Inflammation and Gut-Brain Axis", Normandie University, 76183 Rouen, France.
- Institute of Research and Innovation in Biomedicine (IRIB), UNIROUEN, Normandie University, 76183 Rouen, France.
- Department of Nutrition, Rouen University Hospital, 76183 Rouen, France.
| | - Asma Amamou
- UNIROUEN, INSERM UMR 1073 "Nutrition, Inflammation and Gut-Brain Axis", Normandie University, 76183 Rouen, France.
- Institute of Research and Innovation in Biomedicine (IRIB), UNIROUEN, Normandie University, 76183 Rouen, France.
| | - Séverine Nobis
- UNIROUEN, INSERM UMR 1073 "Nutrition, Inflammation and Gut-Brain Axis", Normandie University, 76183 Rouen, France.
- Institute of Research and Innovation in Biomedicine (IRIB), UNIROUEN, Normandie University, 76183 Rouen, France.
| | - Alexis Goichon
- UNIROUEN, INSERM UMR 1073 "Nutrition, Inflammation and Gut-Brain Axis", Normandie University, 76183 Rouen, France.
- Institute of Research and Innovation in Biomedicine (IRIB), UNIROUEN, Normandie University, 76183 Rouen, France.
| | - Emmeline Salameh
- UNIROUEN, INSERM UMR 1073 "Nutrition, Inflammation and Gut-Brain Axis", Normandie University, 76183 Rouen, France.
- Institute of Research and Innovation in Biomedicine (IRIB), UNIROUEN, Normandie University, 76183 Rouen, France.
| | - Wafa Bahlouli
- UNIROUEN, INSERM UMR 1073 "Nutrition, Inflammation and Gut-Brain Axis", Normandie University, 76183 Rouen, France.
- Institute of Research and Innovation in Biomedicine (IRIB), UNIROUEN, Normandie University, 76183 Rouen, France.
| | - Jean-Luc do Rego
- Institute of Research and Innovation in Biomedicine (IRIB), UNIROUEN, Normandie University, 76183 Rouen, France.
- Animal Behavior Facility, SCAC, UNIROUEN, 76183 Rouen, France.
| | - Pierre Déchelotte
- UNIROUEN, INSERM UMR 1073 "Nutrition, Inflammation and Gut-Brain Axis", Normandie University, 76183 Rouen, France.
- Institute of Research and Innovation in Biomedicine (IRIB), UNIROUEN, Normandie University, 76183 Rouen, France.
- Department of Nutrition, Rouen University Hospital, 76183 Rouen, France.
| | - Moïse Coëffier
- UNIROUEN, INSERM UMR 1073 "Nutrition, Inflammation and Gut-Brain Axis", Normandie University, 76183 Rouen, France.
- Institute of Research and Innovation in Biomedicine (IRIB), UNIROUEN, Normandie University, 76183 Rouen, France.
- Department of Nutrition, Rouen University Hospital, 76183 Rouen, France.
| |
Collapse
|
13
|
Salameh E, Meleine M, Gourcerol G, do Rego JC, do Rego JL, Legrand R, Breton J, Aziz M, Guérin C, Coëffier M, Savoye G, Marion-Letellier R. Chronic colitis-induced visceral pain is associated with increased anxiety during quiescent phase. Am J Physiol Gastrointest Liver Physiol 2019; 316:G692-G700. [PMID: 30735453 DOI: 10.1152/ajpgi.00248.2018] [Citation(s) in RCA: 25] [Impact Index Per Article: 5.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 02/07/2023]
Abstract
Inflammatory bowel diseases (IBD) are characterized by repetition of flares and remission periods leading to chronic postinflammatory sequelae. Among postinflammatory sequelae, one-third of patients with IBD are suffering from functional symptoms or psychological comorbidities that persist during remission. The aim of our study was to assess functional and behavioral sequelae of chronic colitis in rats with quiescent intestinal inflammation. Chronic colitis was induced by a weekly intrarectal injection of increasing concentrations of trinitrobenzene sulfonic acid (TNBS) for 3 wk (15-45 mg of TNBS) in 30 rats, whereas the control rats (n = 24) received the vehicle. At 50 days post-TNBS, visceral sensitivity was assessed by visceromotor response to colorectal distension, and transient receptor potential vanilloid type 1 (TRPV1) expression was also quantified in the colon and dorsal root ganglia. Barrier function and inflammatory response were assessed by studying intestinal permeability, tight junction protein, myeloperoxidase activity, histological score, and cytokine production (IL-6, IL-10, and TNF-α). Anxiety behavioral tests were performed from 50 to 64 days after the last TNBS injection. Chronic TNBS induced 1) a visceral hypersensitivity (P = 0.03), 2) an increased colon weight-to-length ratio (P = 0.01), 3) higher inflammatory and fibrosis scores (P = 0.0390 and P = 0.0016, respectively), and 4) a higher colonic IL-6 and IL-10 production (P = 0.008 and P = 0.005, respectively) compared with control rats. Intestinal permeability, colonic production of TNF-α, myeloperoxidase activity, and TRPV1 expression did not differ among groups. Chronic TNBS increased anxiety-related behavior in the open-field test and in the acoustic stress test. In conclusion, chronic colitis induced functional sequelae such as visceral hypersensitivity and increased anxiety with a low-grade intestinal inflammation. Development of a representative animal model will allow defining novel therapeutic approaches to achieve a better management of IBD-related sequelae. NEW & NOTEWORTHY Patients with inflammatory bowel diseases have impaired quality of life. Therapeutic progress to control mucosal inflammation provides us an opportunity to develop novel approaches to understand mechanisms behind postinflammatory sequelae. We used a chronic colitis model to study long-term sequelae on visceral pain, gut barrier function, and psychological impact. Chronic colitis induced functional symptoms and increased anxiety in the remission period. It might define novel therapeutic approaches to achieve a better inflammatory bowel disease-related sequelae management.
Collapse
Affiliation(s)
- Emmeline Salameh
- Institut National de la Santé et de la Recherche Médicale Unit 1073 "Digestive Tract Environment and Nutrition," Normandie University, UNIROUEN, France.,Institute for Research and Innovation in Biomedicine, Normandie University, Union Nationale Inter-Universitaire Rouen , Rouen , France
| | - Mathieu Meleine
- Institut National de la Santé et de la Recherche Médicale Unit 1073 "Digestive Tract Environment and Nutrition," Normandie University, UNIROUEN, France.,Institute for Research and Innovation in Biomedicine, Normandie University, Union Nationale Inter-Universitaire Rouen , Rouen , France
| | - Guillaume Gourcerol
- Institut National de la Santé et de la Recherche Médicale Unit 1073 "Digestive Tract Environment and Nutrition," Normandie University, UNIROUEN, France.,Institute for Research and Innovation in Biomedicine, Normandie University, Union Nationale Inter-Universitaire Rouen , Rouen , France.,Digestive Physiology Department, Charles Nicolle Hospital, Rouen University Hospital , Rouen , France
| | - Jean-Claude do Rego
- Institute for Research and Innovation in Biomedicine, Normandie University, Union Nationale Inter-Universitaire Rouen , Rouen , France.,Behavioural Analysis Platform (Service Commun d'Analyse Comportementale), Institute for Research and Innovation in Biomedicine, University of Rouen-Normandy , Normandy , France
| | - Jean-Luc do Rego
- Institute for Research and Innovation in Biomedicine, Normandie University, Union Nationale Inter-Universitaire Rouen , Rouen , France.,Behavioural Analysis Platform (Service Commun d'Analyse Comportementale), Institute for Research and Innovation in Biomedicine, University of Rouen-Normandy , Normandy , France
| | - Romain Legrand
- Institut National de la Santé et de la Recherche Médicale Unit 1073 "Digestive Tract Environment and Nutrition," Normandie University, UNIROUEN, France.,Institute for Research and Innovation in Biomedicine, Normandie University, Union Nationale Inter-Universitaire Rouen , Rouen , France
| | - Jonathan Breton
- Institut National de la Santé et de la Recherche Médicale Unit 1073 "Digestive Tract Environment and Nutrition," Normandie University, UNIROUEN, France.,Institute for Research and Innovation in Biomedicine, Normandie University, Union Nationale Inter-Universitaire Rouen , Rouen , France
| | - Moutaz Aziz
- Department of Pathology, Charles Nicolle Hospital, Rouen University Hospital , Rouen , France
| | - Charlène Guérin
- Institut National de la Santé et de la Recherche Médicale Unit 1073 "Digestive Tract Environment and Nutrition," Normandie University, UNIROUEN, France.,Institute for Research and Innovation in Biomedicine, Normandie University, Union Nationale Inter-Universitaire Rouen , Rouen , France
| | - Moïse Coëffier
- Institut National de la Santé et de la Recherche Médicale Unit 1073 "Digestive Tract Environment and Nutrition," Normandie University, UNIROUEN, France.,Institute for Research and Innovation in Biomedicine, Normandie University, Union Nationale Inter-Universitaire Rouen , Rouen , France.,Department of Nutrition, Charles Nicolle Hospital, Rouen University Hospital , Rouen , France
| | - Guillaume Savoye
- Institut National de la Santé et de la Recherche Médicale Unit 1073 "Digestive Tract Environment and Nutrition," Normandie University, UNIROUEN, France.,Institute for Research and Innovation in Biomedicine, Normandie University, Union Nationale Inter-Universitaire Rouen , Rouen , France.,Gastroenterology Unit, Charles Nicolle Hospital, Rouen University Hospital , Rouen , France
| | - Rachel Marion-Letellier
- Institut National de la Santé et de la Recherche Médicale Unit 1073 "Digestive Tract Environment and Nutrition," Normandie University, UNIROUEN, France.,Institute for Research and Innovation in Biomedicine, Normandie University, Union Nationale Inter-Universitaire Rouen , Rouen , France
| |
Collapse
|
14
|
Bahdoudi S, Ghouili I, Hmiden M, do Rego JL, Lefranc B, Leprince J, Chuquet J, do Rego JC, Marcher AB, Mandrup S, Vaudry H, Tonon MC, Amri M, Masmoudi-Kouki O, Vaudry D. Neuroprotective effects of the gliopeptide ODN in an in vivo model of Parkinson's disease. Cell Mol Life Sci 2017; 75:2075-2091. [PMID: 29264673 DOI: 10.1007/s00018-017-2727-2] [Citation(s) in RCA: 12] [Impact Index Per Article: 1.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/07/2017] [Revised: 11/13/2017] [Accepted: 12/05/2017] [Indexed: 12/28/2022]
Abstract
Parkinson's disease (PD) is a neurodegenerative disorder characterized by a progressive loss of dopamine (DA) neurons through apoptotic, inflammatory and oxidative stress mechanisms. The octadecaneuropeptide (ODN) is a diazepam-binding inhibitor (DBI)-derived peptide, expressed by astrocytes, which protects neurons against oxidative cell damages and apoptosis in an in vitro model of PD. The present study reveals that a single intracerebroventricular injection of 10 ng ODN 1 h after the last administration of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) prevented the degeneration of DA neurons induced by the toxin in the substantia nigra pars compacta of mice, 7 days after treatment. ODN-mediated neuroprotection was associated with a reduction of the number of glial fibrillary acidic protein-positive reactive astrocytes and a strong inhibition of the expression of pro-inflammatory genes such as interleukins 1β and 6, and tumor necrosis factor-α. Moreover, ODN blocked the inhibition of the anti-apoptotic gene Bcl-2, and the stimulation of the pro-apoptotic genes Bax and caspase-3, induced by MPTP in the substantia nigra pars compacta. ODN also decreased or even in some cases abolished MPTP-induced oxidative damages, overproduction of reactive oxygen species and accumulation of lipid oxidation products in DA neurons. Furthermore, DBI knockout mice appeared to be more vulnerable than wild-type animals to MPTP neurotoxicity. Taken together, these results show that the gliopeptide ODN exerts a potent neuroprotective effect against MPTP-induced degeneration of nigrostriatal DA neurons in mice, through mechanisms involving downregulation of neuroinflammatory, oxidative and apoptotic processes. ODN may, thus, reduce neuronal damages in PD and other cerebral injuries involving oxidative neurodegeneration.
Collapse
Affiliation(s)
- Seyma Bahdoudi
- Laboratory of Neuronal and Neuroendocrine Communication and Differentiation, Institute for Research and Innovation in Biomedicine (IRIB), Normandy University, UNIROUEN, INSERM, U1239, 76821, Mont-Saint-Aignan, France.,University Tunis El Manar, Faculty of Science of Tunis, UR/11ES09, Laboratory of Functional Neurophysiology and Pathology, 2092, Tunis, Tunisia
| | - Ikram Ghouili
- University Tunis El Manar, Faculty of Science of Tunis, UR/11ES09, Laboratory of Functional Neurophysiology and Pathology, 2092, Tunis, Tunisia
| | - Mansour Hmiden
- University Tunis El Manar, Faculty of Science of Tunis, UR/11ES09, Laboratory of Functional Neurophysiology and Pathology, 2092, Tunis, Tunisia
| | - Jean-Luc do Rego
- Regional Cell Imaging Platform of Normandy (PRIMACEN), Normandy University, UNIROUEN, INSERM, 76821, Mont-Saint-Aignan, France.,Behavioral Analysis Platform (SCAC), Normandy University, 76183, Rouen, France
| | - Benjamin Lefranc
- Laboratory of Neuronal and Neuroendocrine Communication and Differentiation, Institute for Research and Innovation in Biomedicine (IRIB), Normandy University, UNIROUEN, INSERM, U1239, 76821, Mont-Saint-Aignan, France.,Regional Cell Imaging Platform of Normandy (PRIMACEN), Normandy University, UNIROUEN, INSERM, 76821, Mont-Saint-Aignan, France
| | - Jérôme Leprince
- Laboratory of Neuronal and Neuroendocrine Communication and Differentiation, Institute for Research and Innovation in Biomedicine (IRIB), Normandy University, UNIROUEN, INSERM, U1239, 76821, Mont-Saint-Aignan, France.,Regional Cell Imaging Platform of Normandy (PRIMACEN), Normandy University, UNIROUEN, INSERM, 76821, Mont-Saint-Aignan, France
| | - Julien Chuquet
- Laboratory of Neuronal and Neuroendocrine Communication and Differentiation, Institute for Research and Innovation in Biomedicine (IRIB), Normandy University, UNIROUEN, INSERM, U1239, 76821, Mont-Saint-Aignan, France
| | - Jean-Claude do Rego
- Behavioral Analysis Platform (SCAC), Normandy University, 76183, Rouen, France
| | - Ann-Britt Marcher
- Department of Biochemistry and Molecular Biology, University of Southern Denmark, 5230, Odense M, Denmark
| | - Susanne Mandrup
- Department of Biochemistry and Molecular Biology, University of Southern Denmark, 5230, Odense M, Denmark
| | - Hubert Vaudry
- Laboratory of Neuronal and Neuroendocrine Communication and Differentiation, Institute for Research and Innovation in Biomedicine (IRIB), Normandy University, UNIROUEN, INSERM, U1239, 76821, Mont-Saint-Aignan, France.,Regional Cell Imaging Platform of Normandy (PRIMACEN), Normandy University, UNIROUEN, INSERM, 76821, Mont-Saint-Aignan, France
| | - Marie-Christine Tonon
- Laboratory of Neuronal and Neuroendocrine Communication and Differentiation, Institute for Research and Innovation in Biomedicine (IRIB), Normandy University, UNIROUEN, INSERM, U1239, 76821, Mont-Saint-Aignan, France
| | - Mohamed Amri
- University Tunis El Manar, Faculty of Science of Tunis, UR/11ES09, Laboratory of Functional Neurophysiology and Pathology, 2092, Tunis, Tunisia
| | - Olfa Masmoudi-Kouki
- University Tunis El Manar, Faculty of Science of Tunis, UR/11ES09, Laboratory of Functional Neurophysiology and Pathology, 2092, Tunis, Tunisia.
| | - David Vaudry
- Laboratory of Neuronal and Neuroendocrine Communication and Differentiation, Institute for Research and Innovation in Biomedicine (IRIB), Normandy University, UNIROUEN, INSERM, U1239, 76821, Mont-Saint-Aignan, France. .,Regional Cell Imaging Platform of Normandy (PRIMACEN), Normandy University, UNIROUEN, INSERM, 76821, Mont-Saint-Aignan, France.
| |
Collapse
|